CN1863778A - 用于治疗血脂异常的化合物及方法 - Google Patents
用于治疗血脂异常的化合物及方法 Download PDFInfo
- Publication number
- CN1863778A CN1863778A CNA2004800295407A CN200480029540A CN1863778A CN 1863778 A CN1863778 A CN 1863778A CN A2004800295407 A CNA2004800295407 A CN A2004800295407A CN 200480029540 A CN200480029540 A CN 200480029540A CN 1863778 A CN1863778 A CN 1863778A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- amino
- azepine
- cycloalkyl
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50973603P | 2003-10-08 | 2003-10-08 | |
| US60/509,736 | 2003-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1863778A true CN1863778A (zh) | 2006-11-15 |
Family
ID=34465112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004800295407A Pending CN1863778A (zh) | 2003-10-08 | 2004-10-07 | 用于治疗血脂异常的化合物及方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7749992B2 (enExample) |
| EP (2) | EP2098512A1 (enExample) |
| JP (1) | JP4773969B2 (enExample) |
| KR (1) | KR20060085675A (enExample) |
| CN (1) | CN1863778A (enExample) |
| AT (1) | ATE442358T1 (enExample) |
| AU (1) | AU2004282101A1 (enExample) |
| BR (1) | BRPI0414186A (enExample) |
| CA (1) | CA2537942A1 (enExample) |
| CY (1) | CY1110537T1 (enExample) |
| DE (1) | DE602004023100D1 (enExample) |
| DK (1) | DK1670768T3 (enExample) |
| EA (1) | EA200600737A1 (enExample) |
| EC (1) | ECSP066484A (enExample) |
| ES (1) | ES2332051T3 (enExample) |
| HR (1) | HRP20090581T1 (enExample) |
| IL (1) | IL173819A0 (enExample) |
| MA (1) | MA28268A1 (enExample) |
| MX (1) | MXPA06003927A (enExample) |
| NO (1) | NO20062074L (enExample) |
| PL (1) | PL1670768T3 (enExample) |
| PT (1) | PT1670768E (enExample) |
| SI (1) | SI1670768T1 (enExample) |
| WO (1) | WO2005037796A1 (enExample) |
| ZA (1) | ZA200602888B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103833636A (zh) * | 2014-03-31 | 2014-06-04 | 武汉武药制药有限公司 | 一种莫扎伐普坦中间体的合成方法 |
| CN108137508A (zh) * | 2015-07-31 | 2018-06-08 | 艾尼纳制药公司 | 5-ht2c受体激动剂和组合物及使用方法 |
| CN117088814A (zh) * | 2023-02-16 | 2023-11-21 | 烟台大学 | 一种三氟甲硫化氮杂-8/9元环化合物的制备方法 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE433984T1 (de) * | 2004-03-26 | 2009-07-15 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidämie |
| CA2570688A1 (en) | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| WO2018155260A1 (ja) * | 2017-02-23 | 2018-08-30 | 株式会社Ihi | Ｏｈラジカル検出プローブ、ｏｈラジカル測定装置、および、ｏｈラジカル測定方法 |
| CN113195475A (zh) | 2018-10-24 | 2021-07-30 | Viiv保健英国第五有限公司 | 人免疫缺陷病毒复制的抑制剂 |
| BR112022020933A2 (pt) | 2020-04-15 | 2022-12-06 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| CN113636977B (zh) * | 2021-09-01 | 2022-12-20 | 温州大学 | 2-芳基苯并氮杂卓及其衍生物的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2905909B2 (ja) * | 1991-04-19 | 1999-06-14 | 大塚製薬株式会社 | バソプレシン拮抗剤 |
| TW270927B (enExample) | 1992-10-16 | 1996-02-21 | Otsuka Pharma Co Ltd | |
| US5484783A (en) | 1994-03-24 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives |
| HUT75160A (en) | 1994-03-24 | 1997-04-28 | Merrell Pharma Inc | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives |
| DK0765314T3 (da) | 1994-06-15 | 2003-08-25 | Otsuka Pharma Co Ltd | Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer |
| GB9523526D0 (en) | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| JPH09214746A (ja) | 1996-02-02 | 1997-08-15 | Ricoh Co Ltd | 画像出力システム及び画像形成装置 |
| US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US6333349B1 (en) | 1997-02-26 | 2001-12-25 | Aventis Pharma Deutschland Gmbh | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法 |
| JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
| US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| HN2000000203A (es) | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| US6664522B2 (en) * | 2000-03-30 | 2003-12-16 | Homer L. Spencer | Method and apparatus for sealing multiple casings for oil and gas wells |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| DK1383734T3 (da) | 2001-04-30 | 2006-05-15 | Pfizer Prod Inc | Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater |
| HUP0400263A2 (hu) | 2001-06-21 | 2005-03-29 | Pfizer Products Inc. | Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény |
| DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| JP2005522424A (ja) | 2002-02-01 | 2005-07-28 | ファイザー・プロダクツ・インク | コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態 |
| ATE493456T1 (de) | 2002-07-01 | 2011-01-15 | Cytec Surface Specialties Sa | Wasserverdünnbare polymervorläufer sowie herstellung und verwendung davon |
| ES2277142T3 (es) | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | Compuesto de dibencilamina y su uso medicinal. |
| MXPA05003456A (es) | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
| EP1601655A2 (en) | 2003-03-04 | 2005-12-07 | Takasago International Corporation | Method for producing optically active amines |
| US20040204450A1 (en) | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| WO2005033082A2 (en) | 2003-09-30 | 2005-04-14 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
| ATE433984T1 (de) | 2004-03-26 | 2009-07-15 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidämie |
| CA2570688A1 (en) | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
-
2004
- 2004-10-07 BR BRPI0414186-5A patent/BRPI0414186A/pt not_active Application Discontinuation
- 2004-10-07 KR KR1020067006837A patent/KR20060085675A/ko not_active Ceased
- 2004-10-07 PT PT04793889T patent/PT1670768E/pt unknown
- 2004-10-07 ES ES04793889T patent/ES2332051T3/es not_active Expired - Lifetime
- 2004-10-07 CN CNA2004800295407A patent/CN1863778A/zh active Pending
- 2004-10-07 US US10/574,649 patent/US7749992B2/en not_active Expired - Fee Related
- 2004-10-07 EP EP09157118A patent/EP2098512A1/en not_active Withdrawn
- 2004-10-07 DK DK04793889T patent/DK1670768T3/da active
- 2004-10-07 HR HR20090581T patent/HRP20090581T1/hr unknown
- 2004-10-07 SI SI200431294T patent/SI1670768T1/sl unknown
- 2004-10-07 PL PL04793889T patent/PL1670768T3/pl unknown
- 2004-10-07 MX MXPA06003927A patent/MXPA06003927A/es not_active Application Discontinuation
- 2004-10-07 AT AT04793889T patent/ATE442358T1/de active
- 2004-10-07 CA CA002537942A patent/CA2537942A1/en not_active Abandoned
- 2004-10-07 EA EA200600737A patent/EA200600737A1/ru unknown
- 2004-10-07 JP JP2006533949A patent/JP4773969B2/ja not_active Expired - Fee Related
- 2004-10-07 EP EP04793889A patent/EP1670768B1/en not_active Expired - Lifetime
- 2004-10-07 DE DE602004023100T patent/DE602004023100D1/de not_active Expired - Lifetime
- 2004-10-07 WO PCT/US2004/030907 patent/WO2005037796A1/en not_active Ceased
- 2004-10-07 AU AU2004282101A patent/AU2004282101A1/en not_active Abandoned
-
2006
- 2006-02-20 IL IL173819A patent/IL173819A0/en unknown
- 2006-04-05 EC EC2006006484A patent/ECSP066484A/es unknown
- 2006-04-07 ZA ZA200602888A patent/ZA200602888B/en unknown
- 2006-05-03 MA MA28999A patent/MA28268A1/fr unknown
- 2006-05-08 NO NO20062074A patent/NO20062074L/no not_active Application Discontinuation
-
2009
- 2009-11-05 CY CY20091101151T patent/CY1110537T1/el unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103833636A (zh) * | 2014-03-31 | 2014-06-04 | 武汉武药制药有限公司 | 一种莫扎伐普坦中间体的合成方法 |
| CN108137508A (zh) * | 2015-07-31 | 2018-06-08 | 艾尼纳制药公司 | 5-ht2c受体激动剂和组合物及使用方法 |
| CN108137508B (zh) * | 2015-07-31 | 2021-08-27 | 艾尼纳制药公司 | 5-ht2c受体激动剂和组合物及使用方法 |
| CN117088814A (zh) * | 2023-02-16 | 2023-11-21 | 烟台大学 | 一种三氟甲硫化氮杂-8/9元环化合物的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| PT1670768E (pt) | 2009-11-20 |
| IL173819A0 (en) | 2006-07-05 |
| KR20060085675A (ko) | 2006-07-27 |
| CY1110537T1 (el) | 2015-04-29 |
| EP1670768B1 (en) | 2009-09-09 |
| WO2005037796A1 (en) | 2005-04-28 |
| DK1670768T3 (da) | 2009-11-09 |
| EP1670768A1 (en) | 2006-06-21 |
| DE602004023100D1 (de) | 2009-10-22 |
| ECSP066484A (es) | 2006-10-10 |
| JP4773969B2 (ja) | 2011-09-14 |
| NO20062074L (no) | 2006-05-08 |
| MXPA06003927A (es) | 2008-02-07 |
| JP2007508301A (ja) | 2007-04-05 |
| EA200600737A1 (ru) | 2006-10-27 |
| ATE442358T1 (de) | 2009-09-15 |
| ES2332051T3 (es) | 2010-01-25 |
| AU2004282101A1 (en) | 2005-04-28 |
| BRPI0414186A (pt) | 2006-10-31 |
| MA28268A1 (fr) | 2006-11-01 |
| HRP20090581T1 (hr) | 2009-12-31 |
| EP2098512A1 (en) | 2009-09-09 |
| SI1670768T1 (sl) | 2010-01-29 |
| ZA200602888B (en) | 2007-11-28 |
| US20070254869A1 (en) | 2007-11-01 |
| CA2537942A1 (en) | 2005-04-28 |
| PL1670768T3 (pl) | 2010-01-29 |
| US7749992B2 (en) | 2010-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1242995C (zh) | 化合物,它们的用途和制备方法 | |
| CN1254474C (zh) | 作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物 | |
| CN1078889C (zh) | 非肽类速激肽受体拮抗剂 | |
| CN1161334A (zh) | 新的取代胍衍生物，其制备方法和其药物用途) | |
| CN1568187A (zh) | 2h－2,3－二氮杂萘－1－酮和其使用方法 | |
| CN1106804A (zh) | 1-苯碘酰-1，3-二氢-2h-苯并咪唑-2-酮衍生物 | |
| CN1289087C (zh) | 作为神经肽y拮抗剂的喹啉衍生物 | |
| CN1527827A (zh) | 治疗性杂环化合物 | |
| CN1585749A (zh) | 类大麻苷受体配体 | |
| CN1897936A (zh) | 环状胍、含有这种化合物的组合物及其使用方法 | |
| CN1665502A (zh) | Mchir拮抗剂 | |
| CN1378533A (zh) | 苯氧基丙胺类化合物 | |
| CN1361779A (zh) | 新化合物 | |
| CN1656075A (zh) | 喹啉衍生物和其作为5－ht6配体的用途 | |
| CN1113236A (zh) | 非肽基速激肽受体拮抗剂 | |
| CN1751047A (zh) | 可用于治疗的三唑化合物 | |
| CN1732146A (zh) | 钾通道功能的环烷基抑制剂 | |
| CN1930160A (zh) | Hiv整合酶抑制剂 | |
| CN1701068A (zh) | 新颖的化合物和它们的用途 | |
| CN1592745A (zh) | 治疗用苯并－γ－吡喃酮化合物 | |
| CN1468211A (zh) | 亚硝基二苯胺衍生物 | |
| CN1863789A (zh) | 取代的异喹啉酮 | |
| CN1524077A (zh) | 治疗用苯并二氢吡喃化合物 | |
| CN1863778A (zh) | 用于治疗血脂异常的化合物及方法 | |
| CN1478092A (zh) | 苯并噁嗪酮衍生物及其制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |